Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.

James William L BrownFerran Prados CarrascoArman EshaghiCarole H SudreTom ButtonMatteo PardiniRebecca S SamsonSebastien OurselinClaudia Am Gandini Wheeler-KingshottJoanne L JonesAlasdair J ColesDeclan T Chard

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2019)

Untreated, abnormal periventricular gradients worsen with time, but appear reversible with peripheral immunotherapy. Baseline gradients - but not lesion loads or brain volumes - may predict on-treatment relapses. Larger confirmatory studies are required.

Keyphrases

multiple sclerosis
white matter
combination therapy
cerebral ischemia
replacement therapy